Laurus Labs Ltd

Net profit of Laurus Labs rose 125.49% to Rs 367.60 crore in the quarter ended June 2026 as against Rs 163.02 crore during the previous quarter ended June 2025. Sales rose 29.10% to Rs 2026.31 crore in the quarter ended June 2026 as against Rs 1569.57 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales2026.311569.57 29 OPM %31.5024.35 - PBDT605.23341.06 77 PBT481.36224.22 115 NP367.60163.02 125 Powered by Capital Market - Live

Gross margin improved to 62.7% in Q1 FY27 from 59.4% in Q1 FY26. Profit before tax (PBT) surged 114.5% YoY to Rs 481.36 crore in Q1 FY27 from Rs 224.22 crore in Q1 FY26. EBITDA jumped 65.6% YoY to Rs 644 crore in Q1 FY27 from Rs 389 crore in Q1 FY26. EBITDA margin expanded to 31.8% from 24.8% in Q1 FY26. In Q1 FY27, Laurus Labs' Contract Development and Manufacturing Organization (CDMO) revenue surged 67% YoY to Rs 870 crore, driven by a 69% increase in small molecules revenue and a 21% rise in the bio business. Revenue from the Affordable Medicines (Generics) division increased 10% YoY to Rs 1,156 crore, with API revenue rising 3% to Rs 654 crore and finished dosage formulations (FDF) revenue increasing 22% to Rs 502 crore. ARV revenue grew 3% YoY to Rs 669 crore during the quarter. Dr. Satyanarayana Chava, founder & chief executive officer, commented, Laurus has delivered record quarterly revenue with expanded profitability and continued its portfolio transformation. This was driven by growing commercial deliveries within CDMO and continued strength in the affordable medicines portfolio. During the quarter, we strengthened our integrated offerings, niche capabilities that matter most to our clients. We also achieved important milestones, including agreement to in-license two Antibody Drug Conjugates (ADCs) and securing final handover of a new land parcel, reinforcing our long-term growth strategy. I am pleased with our progress and excited about the next wave of business opportunities driving confidence in our ability to deliver sustained growth and value creation. V V Ravi Kumar, executive director & chief financial officer, commented, 'We delivered a strong operating performance in Q1 despite challenging macroeconomic volatility. We are pleased to see sustained momentum across both the CDMO and Affordable Medicine divisions. We have achieved a revenue of Rs 2,026 crore, representing 29% growth and EBITDA of Rs 644 crore, representing 66% growth. The EBITDA margins were strong and consistently improved at 31.8%, supported by improvement in capacity utilization and operating leverage. Gross margins improved by over 3 percentage points to 62.7% due to favorable segment mix. Our commercial and operational execution continues to enable us to generate strong results and we are continuing on our key CAPEX program to drive near and long-term growth.' Laurus Labs is a research-driven pharmaceutical and biotechnology company. It develops and manufactures select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro-therapeutics. It offers end-to-end CDMO services, supporting innovators from early-stage development to commercial production.Powered by Capital Market - Live

Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 July 2026.

Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 1475.1, up 2.73% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.73% on the day, quoting at 23927.6. The Sensex is at 76562.32, down 0.69%. Laurus Labs Ltd has added around 8.76% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 1.53% in last one month and is currently quoting at 24762.9, up 1.17% on the day. The volume in the stock stood at 26.77 lakh shares today, compared to the daily average of 18.03 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1471.5, up 2.47% on the day. Laurus Labs Ltd is up 120.31% in last one year as compared to a 4.46% fall in NIFTY and a 15.59% fall in the Nifty Pharma index.The PE of the stock is 104.38 based on TTM earnings ending March 26.Powered by Capital Market - Live

Laurus Labs has allotted 3,93,001 equity shares under ESOP on 04 June 2026. The total paid up capital of the Company after the above allotments stands at Rs.1,08,04,99,166/- divided into 54,02,49,583 equity shares of Rs.2/- each.

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 1389.5, up 1.14% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.07% on the day, quoting at 23930.5. The Sensex is at 75999.31, down 0.01%. Laurus Labs Ltd has added around 27.42% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 6.68% in last one month and is currently quoting at 24659.2, up 0.19% on the day. The volume in the stock stood at 9.51 lakh shares today, compared to the daily average of 25.19 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1396.3, up 1.11% on the day. Laurus Labs Ltd is up 127.6% in last one year as compared to a 3.32% fall in NIFTY and a 15.48% fall in the Nifty Pharma index.The PE of the stock is 100.13 based on TTM earnings ending March 26.Powered by Capital Market - Live

Laurus Labs Ltd gained for a fifth straight session today. The stock is quoting at Rs 1280.4, up 1.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 1.22% on the day, quoting at 23526.15. The Sensex is at 74972.87, down 1.37%. Laurus Labs Ltd has risen around 17.71% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has risen around 8.59% in last one month and is currently quoting at 24170.45, down 0.71% on the day. The volume in the stock stood at 13.65 lakh shares today, compared to the daily average of 22.25 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 1284.3, up 1.22% on the day. Laurus Labs Ltd is up 115.1% in last one year as compared to a 4.28% drop in NIFTY and a 12.36% drop in the Nifty Pharma index.The PE of the stock is 92.31 based on TTM earnings ending March 26.Powered by Capital Market - Live

Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 1227.6, up 1.75% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.64% on the day, quoting at 24170.45. The Sensex is at 77285.81, down 0.72%. Laurus Labs Ltd has added around 13.28% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 9.03% in last one month and is currently quoting at 24135.5, down 0.01% on the day. The volume in the stock stood at 14.75 lakh shares today, compared to the daily average of 21.07 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 1230.1, up 1.49% on the day. Laurus Labs Ltd is up 108.49% in last one year as compared to a 0.68% gain in NIFTY and a 14.53% gain in the Nifty Pharma index.The PE of the stock is 87.93 based on TTM earnings ending March 26.Powered by Capital Market - Live

Net profit of Laurus Labs rose 19.46% to Rs 279.14 crore in the quarter ended March 2026 as against Rs 233.67 crore during the previous quarter ended March 2025. Sales rose 5.31% to Rs 1811.57 crore in the quarter ended March 2026 as against Rs 1720.30 crore during the previous quarter ended March 2025. For the full year,net profit rose 148.04% to Rs 888.79 crore in the year ended March 2026 as against Rs 358.32 crore during the previous year ended March 2025. Sales rose 22.67% to Rs 6812.90 crore in the year ended March 2026 as against Rs 5553.96 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1811.571720.30 5 6812.905553.96 23 OPM %28.2724.45 -26.0919.00 - PBDT483.47422.77 14 1661.93914.38 82 PBT361.37312.34 16 1181.88484.29 144 NP279.14233.67 19 888.79358.32 148 Powered by Capital Market - Live

Laurus Labs announced that the 21th Annual General Meeting(AGM) of the company will be held on 2 July 2026.